AI
TVTX icon

Atom Investors’s Travere Therapeutics TVTX Stock Holding History

Atom Investors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,331
Closed -$223K – 810
2025
Q3 		$223K Sell
9,331
-27,036
-74% -$508K 0.02% 495
2025
Q2 		$538K Sell
36,367
-3,444
-9% -$57.1K 0.05% 345
2025
Q1 		$713K Buy
+39,811
New +$808K 0.09% 254
2020
Q3 		– Sell
-26,782
Closed -$547K – 625
2020
Q2 		$547K Sell
26,782
-163,354
-86% -$2.6M 0.04% 261
2020
Q1 		$2.77M Buy
190,136
+40,135
+27% +$604K 0.24% 94
2019
Q4 		$2.13M Sell
150,001
-71,787
-32% -$917K 0.17% 128
2019
Q3 		$2.57M Buy
221,788
+54,758
+33% +$905K 0.18% 140
2019
Q2 		$3.36M Buy
+167,030
New +$3.3M 0.22% 135

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Atom Investors's TVTX Position: Q4 2025 in Review

Atom Investors sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 9,331 shares — an estimated $223K sold.

Atom Investors first reported a position in TVTX in Q2 2019 and held it in 8 quarters. The position peaked at $3.36M in Q2 2019. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Atom Investors reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Atom Investors sold 9,331 Travere Therapeutics shares in Q4 2025, an estimated $223K.
  • Atom Investors first reported a position in Travere Therapeutics in Q2 2019 and held it in 8 quarters.
  • Atom Investors's Travere Therapeutics position peaked at $3.36M in Q2 2019.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.